Mylan has received a long-awaited approval for the first US generic rival to GlaxoSmithKline’s (GSK’s) Advair Diskus (fluticasone/salmeterol) asthma treatment, putting the firm around a year ahead of other US generics being pursued by competitors Sandoz and Hikma.
Mylan has not yet announced launch plans for its Wixela Inhub version – which has been approved in three strengths,...




